Intellia Therapeutics Receives European Union Orphan Drug Designation for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema
14 nov. 2023 07h30 HE
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative single-dose...
Intellia Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
09 nov. 2023 07h30 HE
|
Intellia Therapeutics, Inc.
FDA cleared NTLA-2001 IND application for first in vivo CRISPR candidate to enter late-stage clinical development; on track to initiate the MAGNITUDE pivotal Phase 3 trial in patients with...
Intellia Presents New Interim Data from the Ongoing Phase 1 Study of NTLA-2001 at the 4th International ATTR Amyloidosis Meeting
02 nov. 2023 07h00 HE
|
Intellia Therapeutics, Inc.
Updated data from over 60 patients showed consistent, deep and durable serum TTR reduction achieved with a single dose of NTLA-2001, including in 29 patients who have now reached 12 months or more of...
Intellia Therapeutics to Present Updated Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis and Hold Conference Call to Discuss Third Quarter 2023 Earnings in November
26 oct. 2023 07h30 HE
|
Intellia Therapeutics, Inc.
New interim NTLA-2001 clinical data to be presented at the 4th International ATTR Amyloidosis Meeting on November 2; data to include safety and both absolute and percent change in serum TTR reduction...
Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application to Initiate a Pivotal Phase 3 Trial of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy
18 oct. 2023 07h00 HE
|
Intellia Therapeutics, Inc.
NTLA-2001 is the first-ever investigational in vivo CRISPR-based gene editing therapy cleared to enter late-stage clinical development CAMBRIDGE, Mass., Oct. 18, 2023 (GLOBE NEWSWIRE) --...
Intellia Therapeutics Receives Priority Medicines (PRIME) Designation From the European Medicines Agency for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema
13 oct. 2023 08h38 HE
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics...
Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases
03 oct. 2023 07h00 HE
|
Intellia Therapeutics, Inc.
Collaboration combines Intellia’s leading genome editing platform, including its proprietary Nme2Cas9 technology, with Regeneron’s proprietary antibody-targeted viral vector delivery technologies to...
Intellia Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress
03 août 2023 07h30 HE
|
Intellia Therapeutics, Inc.
Completed identification of all patients for the Phase 2 study of NTLA-2002 for the treatment of hereditary angioedema (HAE) Plans to initiate a global pivotal Phase 3 study of NTLA-2002 as early as...
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2023 Earnings and Company Updates
27 juil. 2023 07h30 HE
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics...
Intellia Therapeutics Announces New Positive Clinical Data from Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema (HAE)
11 juin 2023 08h30 HE
|
Intellia Therapeutics, Inc.
Extended Phase 1 data reinforce the potential of NTLA-2002 to be a functional cure for people living with hereditary angioedema (HAE)Across all patients (n=10), a single dose of NTLA-2002 led to a 95%...